The Technical Analyst
Cellectar Biosciences Inc [CLRB]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cellectar Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.61% $3.06
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 98.72 mill |
| EPS: | -3.11 |
| P/E: | -0.980 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 32.26 mill |
| Avg Daily Volume: | 1.096 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.980 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.17x |
| Company: PE -0.980 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.737 (-75.90%) $-2.32 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.77 - 3.33 ( +/- 9.25%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-23 | Lea Darrell Shane | Buy | 100 000 | Stock option (right to buy) |
| 2023-12-08 | Lea Darrell Shane | Buy | 39 599 | Common Stock |
| 2023-06-23 | Kolean Chad J | Buy | 104 000 | Stock option (right to buy) |
| 2023-12-08 | Kolean Chad J | Buy | 42 554 | Common Stock |
| 2023-12-08 | Shustov Andrei | Buy | 47 856 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 93 transactions |
| Buy: 8 845 700 | Sell: 235 734 |
Forecast:
16:00 - $3.05
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.05
Forecast 2: 16:00 - $3.05
Forecast 3: 16:00 - $3.05
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.06 (-1.61% ) |
| Volume | 1.043 mill |
| Avg. Vol. | 1.096 mill |
| % of Avg. Vol | 95.18 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CLRB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $3.48 | N/A | Active |
|---|
CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Latest Press Releases
2024-03-27 06:40:00 - Press Release
Cellectar Biosciences Reports Financial Results For Year Ended 2023 And Provides A Corporate Update
Florham park, n.j., march 27, 2024 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended december 31, 2023, and provided a corporate update.
2024-03-20 06:40:00 - Press Release
Cellectar Biosciences To Announce 2023 Year End Earnings Results And Host A Conference Call On Wednesday, March 27, 2024
Florham park, n.j., march 20, 2024 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the year ended december 31, 2023, on wednesday, march 27, 2024. management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am eastern time. details for the call are as follows:
2024-03-14 08:52:00 - Press Release
Cellectar Biosciences To Present At The 36th Annual Roth Conference
Florham park, n.j., march 14, 2024 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that jim caruso, president and chief executive officer of cellectar, will present an overview of the company in a fireside chat at the upcoming 36th annual roth conference taking place on march 17 to 19, 2024 in laguna niguel, ca. details of the fireside chat are as follows:
2024-03-04 06:40:00 - Press Release
Cellectar Biosciences Reports High Rate Of Complete Remission In Investigator Initiated Phase I Study Of Iopofosine In Combination With External Beam Radiotherapy In Recurrent Head And Neck Cancer
Florham park, n.j., march 04, 2024 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that iopofosine i 131 in combination with external beam radiation therapy (ebrt) was safe and tolerated in a spore grant supported investigator-initiated phase 1 clinical trial.
2024-02-07 06:40:00 - Press Release
Cellectar Biosciences To Present At The Oppenheimer 34th Annual Healthcare Life Sciences Conference
Florham park, n.j., feb. 07, 2024 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that james caruso, president and chief executive officer of cellectar, will present an overview of the company at the upcoming oppenheimer 34th annual healthcare life sciences conference being held virtually. details of the presentation are as follows:
Latest News
2024-03-27 12:27:02 - Seeking Alpha
Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript
2024-03-20 06:40:00 - GlobeNewsWire
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows:
2024-03-14 08:52:00 - GlobeNewsWire
Cellectar Biosciences to Present at the 36th Annual Roth Conference
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jim Caruso, president and chief executive officer of Cellectar, will present an overview of the company in a fireside chat at the upcoming 36th Annual Roth Conference taking place on March 17 to 19, 2024 in Laguna Niguel, CA. Details of the fireside chat are as follows:
2024-02-12 01:34:26 - Seeking Alpha
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss
Cellectar Biosciences is a developmental biotech focused on a radiolabeled phospholipid for hematologic malignancies, with a focus on Waldenstrom's macroglobulinemia. Their most advanced development is in Waldenstrom's, with positive trial results and plans to file for Accelerated Approval. The company has a strong chance at approval but faces cash concerns and the challenge of a small market size for its drug.
2024-02-07 06:40:00 - GlobeNewsWire
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and chief executive officer of Cellectar, will present an overview of the company at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually. Details of the presentation are as follows:
2024-01-08 08:37:25 - InvestorPlace
Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today?
Cellectar Biosciences (NASDAQ: CLRB ) stock is heading higher on Monday after the company posted positive results from its CLOVER WaM study of iopofosine I 131. According to a press release from the company, iopofosine I 131 performed well in the trial as a potential first-in-class, targeted radiotherapy candidate to treat patients with relapsed/refractory Waldenstrom's macroglobulinemia that have already undergone a minimum of two previous forms of therapy.
2024-01-08 06:41:58 - Reuters
Cellectar's blood cancer therapy succeeds in trial
Cellectar Biosciences said on Monday its therapy iopofosine for Waldenstrom's macroglobulinemia, a type of blood cancer, met the main goal when tested in patients who received at least two prior lines of therapy.
2023-12-05 08:30:00 - GlobeNewsWire
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
FLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, Cellectar's chief operating officer (COO), will deliver a presentation and co-chair the 5th Annual Targeted Radiopharmaceuticals Summit Europe, being held December 5-7, 2023 in Berlin, Germany.
2023-11-02 14:19:05 - Seeking Alpha
Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Call Transcript
Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors James Caruso - CEO Chad Kolean - CFO Shane Lea - CCO Andrei Shustov - SVP, Medical Conference Call Participants Jonathan Aschoff - ROTH MKM Jeffrey Jones - Oppenheimer Ahu Demir - Ladenburg Jason McCarthy - Maxim Group Operator Good morning, and welcome to Cellectar Biosciences Third Quarter 2023 Update Call. Today's conference is being recorded.
2022-03-21 13:32:02 - Benzinga
Here's Why Cellectar Biosciences Shares Are Rising
Cellectar Biosciences Inc (NASDAQ: CLRB) shares are trading higher by 12.1% at $0.61 after the company reported better-than-expected fourth-quarter EPS results. Cellectar Biosciences beat estimated earnings by 10.0%, reporting an EPS loss of 9 cents versus an estimate of a.